Clues in SCAF, a DOAC antidote trial, another negative lytic trial in stroke, JAMA changes to observational studies, and BP in stroke care are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. ARTESIA Substudy Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology  https://www.medscape.com/viewarticle/998215 ARTESIA Substudy NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062 ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234 II. DOAC Reversal ANNEXA-1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2313040 III. Lytic Therapy in Acute Stroke Thrombolysis Offers No Benefit for Mild Stroke https://www.medscape.com/viewarticle/iv-thrombolysis-offers-no-benefit-mild-stroke-2024a10009p7 TEMPO-2 Trial https://doi.org/10.1016/S0140-6736(24)00921-8 The Case Against Thrombolytic Therapy in Stroke IV. Observational Research JAMA Special Communication https://jamanetwork.com/journals/jama/fullarticle/2818746 JAMA editors note https://jamanetwork.com/journals/jama/fullarticle/2818747 V. Aggressive BP Control in Stroke Guidelines on Rapid BP Reduction in Acute Ischemic Stroke Challenged https://www.medscape.com/viewarticle/guidelines-rapid-bp-reduction-acute-ischemic-stroke-2024a10009pe TRUTH Trial  https://doi.org/10.1016/S1474-4422(24)00177-7 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net